Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Ortojorjia | Pharma | 36.6% | 86th pct | 110 |
| SBC Global | Pharma | 25.4% | 69th pct | 110 |
| Vorld Pharma | Pharma | 10.0% | 36th pct | 110 |
| Kalandadze | Pharma | -5.4% | 7th pct | 110 |
| Geo - Pharma | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Line item | Vorld Pharma | Ortojorjia | Kalandadze | SBC Global | Geo - Pharma |
|---|---|---|---|---|---|
| Total Current Assets | 1,286 | 3,032 | 416 | 1,403 | — |
| Total Non-Current Assets | 3,504 | 78 | 191 | 7 | — |
| TOTAL ASSETS | 4,790 | 3,110 | 607 | 1,410 | — |
| Total Current Liabilities | 2,280 | 0 | 305 | 402 | — |
| Total Non-Current Liabilities | 11 | 170 | 0 | 2 | — |
| TOTAL LIABILITIES | 2,291 | 170 | 305 | 404 | — |
| Total Equity | 2,499 | 2,940 | 302 | 1,006 | — |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | — |
| Total Debt | 800 | 170 | 0 | 0 | — |
| Cash & Equivalents | 120 | 1,244 | 7 | 13 | — |
| Net Debt | 680 | -1,075 | -7 | -13 | — |
Not every picked company reports every selected year — FY2024: no filing for Geo - Pharma. Those cells are left blank (no filing), not zero.